logo

News

14 Sep 2018

EpimAb Biotherapeutics Announces IND Filing for EMB01 in China and the US

EpimAb Biotherapeutics Announces IND Filing for EMB01 in China and the US IND Filing Marks Further Progress Towards the First Clinical Trial with the Company’s Novel Bispecific Antibody Format Shanghai, China, September 14, 2018 — EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced today that it has filed an IND for its most advanced therapeutic development candidate EMB01. The applications were simultaneously submitted to the U.S. Food and Drug Administration (FDA) and the National Medical Products […]

23 Apr 2018

EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce Development Collaboration on Epimab’s FIT012 Bispecific Antibody Program

Zhejiang Teruisi Biopharmaceutical to take the lead in developing the program in China, Epimab retains worldwide commercial rights outside of China Shanghai/Suzhou, and Huzhou, China, April 23, 2018 – EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Zhejiang Teruisi Biopharmaceutical, a company specialized in the development of biologics, today announced a development collaboration on a bispecific antibody program discovered by EpimAb. Under the terms of the agreement, Zhejiang Teruisi Biopharmaceutical, Inc. will gain access to EpimAb’s Fabs-In-Tandem […]

27 Feb 2018

EpimAb Biotherapeutics Appoints Industry Veteran Bin Peng as Chief Medical Officer

Former Global Head of Oncology Translational Medicine at Novartis in China to Guide Transformation of EpimAb into Clinical Stage Oncology Company Shanghai, China, February 27, 2018 – EpimAb Biotherapeutics, a biologics company based in Shanghai, China, specialized in developing a portfolio of bispecific antibodies, announced today that Bin Peng, MD, PhD, has joined the company as its first Chief Medical Officer. Dr. Peng, former Global Head of Oncology Translational Medicine Shanghai CNIBR at Novartis, was a major contributor to the […]

31 May 2017

EpimAb Biotherapeutics Collaborates with WuXi Biologics to Advance Lead Bispecific Antibody Candidate towards Clinical Development

First FIT-Ig® Cancer Therapy Expected to Enter the Clinic in 2018 Shanghai, China, May 31, 2017 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and WuXi Biologics, a WuXi AppTec Affiliate, announced today a collaboration to advance EpimAb’s first candidate, EMB-01, towards IND-filing. EMB-01 is a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig® that has shown efficacy in multiple preclinical cancer models. Under the agreement, WuXi will be responsible for establishing the chemistry, manufacturing and […]

25 Apr 2017

EpimAb Biotherapeutics Raises $25M in Series A Financing From International Consortium to Advance Pipeline of Novel Bispecific Antibodies

Shanghai, China, April 25, 2017 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced today the completion of a $25 million Series A financing round. The financing was led by Oriza Seed Capital and included investments from Decheng Capital, 3E Bioventures Capital and the Trend Investment Group. With the funding, Epimab will advance its proprietary bispecific platform technology and build a pipeline of therapeutic candidates in immuno-oncology and other areas with a high unmet medical need. […]

11 Oct 2016

Kymab and EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement

Cambridge/UK and Shanghai/China, October 11, 2016 – Kymab, a leading human monoclonal antibody biopharmaceutical company, and EpimAb Biotherapeutics, an emerging biopharmaceutical company specializing in bispecific antibodies, today announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets. The parties will focus their efforts on immuno-oncology and will combine EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to generate multiple bispecific antibodies combined with antibodies sourced from Kymab’s proprietary Kymouse® platform. Kymab will have the development and commercialization rights […]

06 Jun 2016

EpimAb Biotherapeutics and Innovent Biologics Announce Multi-Target Bispecific Antibody Collaboration

Shanghai/Suzhou, June 6th, 2016 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Innovent Biologics, one of the leading biopharmaceutical companies in China, today announced a multiple target agreement for the development of bispecific antibodies. Under the terms of the agreement, Innovent will gain access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China. In return for commercialization […]